AffyImmune Appoints Dr. Daniel Janse as CEO
“We are thrilled to welcome Dr. Janse as the new CEO of AffyImmune” AffyImmune, a clinical-stage biotechnology company focused on pioneering first-in-class CAR T cell therapies, has announced the appointment of Daniel Janse, Ph.D., as President and Chief Executive Officer. With two decades of experience in biopharmaceutical research and development, operations, and leadership, Dr. Janse…